The first standardized form of medical cannabis.
C3® International, Inc. was formed to leverage first mover advantage and play a leadership role in the emergent cannabinoid therapeutics health sector. C3® is the manufacturer of the Idrasil® Intellectual Property.
Clinical EndoCannabinoid Deficiency (CECD)
Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. READ MORE